Pathologic Complete Response to Neoadjuvant Dual Checkpoint Blockade with Durvalumab Plus Tremelimumab in Advanced-Stage HCC: A Case Report Authors: Leonard Bopp, Meinrad Beer, Stefan Andreas Schmidt, Thomas Seufferlein, Thomas Ettrich, Nuh N Rahbari, Emrullah Birgin Published: 2026 ABSTRACT AbstractCurrent guidelines recommend systemic therapy for patients with Barcelona Clinic Liver Cancer (BCLC) Stage C hepatocellular carcinoma (HCC). However, this population is highly heterogeneous regarding tumor burden, vascular invasion, liver function, and performance status, enabling opportunities for individualized, multimodal strategies. We report the case of a 72-year-old male with a 10 × 7.5 cm HCC and portal vein infiltration involving both the right anterior and left portal branches, in the setting of a past hepatitis C. Due to extensive vascular invasion, the tumor board advised primary systemic therapy with dual immune checkpoint inhibition using Durvalumab and Tremelimumab. After four months of neoadjuvant immunotherapy, restaging showed a partial response with stable liver function. Due to this favorable outcome, the tumor board reassessed resectability and recommended secondary resection. The patient underwent a robotic two-stage hepatectomy with ligation of the right anterior and left portal branches (ALPPS), followed by completion left trisectionectomy 14 days later. Final pathology revealed a complete pathologic response to immunotherapy. At twelve months, the patient remained recurrence-free, with preserved liver function and improved quality of life. This case highlights the potential of neoadjuvant dual checkpoint blockade to induce tumor regression in selected patients with BCLC-C HCC, thereby expanding surgical candidacy even in the presence of macroscopic vascular invasion. Combined with advances in robotic hepatectomy, such multimodal approaches may redefine resectability criteria. Introduction Hepatocellular carcinoma (HCC) is the sixth most common malignancy globally and a leading cause of cancer-related death.1 By the year 2050, the incidence of HCC is expected to double. This is mainly driven by increasing rates of metabolic dysfunction-associated steatotic liver disease while cases linked to viral hepatitis are declining.2 Five-year survival for advanced or metastatic HCC remains poor with median survival ranging from 6 to 13 months depending on treatment and disease characteristics. Management of localized HCC remains complex with therapeutic options ranging from transplantation to ablation and resection. Classification of HCC follows the Barcelona Clinic Liver Cancer (BCLC) scheme which serves as the basis for the current treatment algorithm.3,4 The recent BCLC 2026 update has introduced the CUSE framework (Complexity, Uncertainty, Subjectivity, Emotion) into clinical practice, attempting to provide a structured methodology to define therapeutic goals and weigh treatment options against evidence gaps.3 While providing more flexibility, this framework adds another layer to the decision-making process and increases the complexity of treatment options. In resectable hepatocellular carcinoma outside the Milan Criteria, liver resection has been shown to provide better overall survival (OS) compared to transcatheter arterial chemoembolization (TACE).5,6 Patients with macrovascular invasion, extrahepatic disease and reduced performance status are considered as advanced-stage HCC with impaired quality of life. Nonetheless, the era of immunotherapy has significantly altered systemic treatment paradigms for this patient cohort.7–9 In particular, combination strategies based on Programmed Death-Ligand 1 (PD-L1) inhibition have demonstrated improved survival outcomes compared to Tyrosine Kinase Inhibitors (TKIs) in advanced-stage HCC.10 Increasingly, these agents are being explored in conversion strategies aimed at downstaging tumors with minor systemic toxicity and impact on quality of life to enable surgical intervention.11 However, uncertainties remain regarding which patients with advanced HCC may benefit from treatment intensification and conversion to curative-intent surgery. Moreover, the adoption of robotic liver surgery for the treatment of HCC may potentially minimize the risk of posthepatectomy liver failure and improve postoperative outcomes. For patients undergoing major hepatectomy this includes the use of regenerative surgery to enable oncologic resection with preserved liver function. In the present report, we describe a case of a patient with an advanced HCC and secondary robotic liver resection following neoadjuvant immunotherapy after significant tumor downstaging with pathologic complete response. Case Report We report the case of a 72-year-old male patient with an advanced-stage HCC in the setting of a past hepatitis C virus (HCV) infection. The patient initially presented to the general practitioner due to unintended weight loss and a deterioration of general condition. Initial ultrasound revealed a large, perfused lesion in the liver. Further computed tomography (CT) imaging confirmed the 100 mm x 75 mm mass in segments IV, V and VIII infiltrating the left and right anterior portal veins (Figure 1). Figure 1Initial CT imaging at the time of diagnosis. (a) Coronal view of the 150 mm x 90 mm x 80 mm HCC in Segments IV, V, VIII during the arterial phase (star). The umbilical portion of the left portal vein is infiltrated by the tumor (triangle). (b) Axial view of the lesion (star) with infiltration of the right anterior portal vein and “wash-in” characteristics during the arterial phase. Infiltration of the right anterior portal vein (arrow). (c) Axial view of the lesion (star) during the portal venous phase showing “wash-out”.The image shows three CT images depicting the tumor in the liver at the time of diagnosis. Initial CT imaging at the time of diagnosis. (a) Coronal view of the 150 mm x 90 mm x 80 mm HCC in Segments IV, V, VIII during the arterial phase (star). The umbilical portion of the left portal vein is infiltrated by the tumor (triangle). (b) Axial view of the lesion (star) with infiltration of the right anterior portal vein and “wash-in” characteristics during the arterial phase. Infiltration of the right anterior portal vein (arrow). (c) Axial view of the lesion (star) during the portal venous phase showing “wash-out”. The patient was referred to our tertiary care center, and a biopsy of the lesion confirmed a moderately differentiated (G2 Grading) advanced-stage HCC. The patient had an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 1, and liver function was preserved without cirrhosis. Baseline laboratory work is summarized in Table 1 and Table 2. Previous HCV-therapy included treatments with Interferon, Ribavirin, Ledipasvir and Sofosbuvir.Table 1Blood Laboratory Values Prior to Systemic TreatmentNa+143 mmol/lAlb40 g/lK+4.1 mmol/lAFP4 µg/lCa2+2.5 mmol/lPT-activity67%Krea74 µmol/lPT-INR1.1eGFR88 mL/minPTT31.1 sec.T-Bil13 µmol/lWBC7.5 Giga/lAST93 U/lRBC4.6 Tera/lALT107 U/lHb12.0 g/dlGGT594 U/lHt0.37 L/lAKP581 U/lPlt359 Giga/lLDH162 U/lCRP0.8 mg/lAbbreviations: Na+, Sodium; K+, Potassium; Ca2+, Calcium; Krea, Creatinine; eGFR, estimated Glomerular Filtration Rate; T-Bil, Total Bilirubin; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; GGT, Gamma-Glutamyl Transferase; AKP, Alkaline Phosphatase; LDH, Lactate Dehydrogenase; Alb, Albumin; AFP, Alpha-fetoprotein; PT-activity, Prothrombin Time Activity; PT-INR, Prothrombin Time International Normalized Ratio; PTT, Partial Thromboplastin Time; WBC, White Blood Cells; RBC, Red Blood Cells; Hb, Haemoglobin; Ht, Haematocrit; Plt, Thrombocytes; CRP, C-Reactive Protein. Table 2Virology Prior to Systemic TreatmentAnti-HCVpositiveHCV-RNAN.D.HBs-AgN.D.Anti-HBs75 IU/lAbbreviations: Anti-HCV, Hepatitis C Virus Antibody; HCV-RNA, Hepatitis C Virus Ribonucleic Acid; HBs-Ag, Hepatitis B surface Antigen; Anti-HBs, Hepatitis B surface antibody; N.D., Not Detected. Table 1Blood Laboratory Values Prior to Systemic TreatmentNa+143 mmol/lAlb40 g/lK+4.1 mmol/lAFP4 µg/lCa2+2.5 mmol/lPT-activity67%Krea74 µmol/lPT-INR1.1eGFR88 mL/minPTT31.1 sec.T-Bil13 µmol/lWBC7.5 Giga/lAST93 U/lRBC4.6 Tera/lALT107 U/lHb12.0 g/dlGGT594 U/lHt0.37 L/lAKP581 U/lPlt359 Giga/lLDH162 U/lCRP0.8 mg/lAbbreviations: Na+, Sodium; K+, Potassium; Ca2+, Calcium; Krea, Creatinine; eGFR, estimated Glomerular Filtration Rate; T-Bil, Total Bilirubin; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; GGT, Gamma-Glutamyl Transferase; AKP, Alkaline Phosphatase; LDH, Lactate Dehydrogenase; Alb, Albumin; AFP, Alpha-fetoprotein; PT-activity, Prothrombin Time Activity; PT-INR, Prothrombin Time International Normalized Ratio; PTT, Partial Thromboplastin Time; WBC, White Blood Cells; RBC, Red Blood Cells; Hb, Haemoglobin; Ht, Haematocrit; Plt, Thrombocytes; CRP, C-Reactive Protein. Blood Laboratory Values Prior to Systemic Treatment Abbreviations: Na+, Sodium; K+, Potassium; Ca2+, Calcium; Krea, Creatinine; eGFR, estimated Glomerular Filtration Rate; T-Bil, Total Bilirubin; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; GGT, Gamma-Glutamyl Transferase; AKP, Alkaline Phosphatase; LDH, Lactate Dehydrogenase; Alb, Albumin; AFP, Alpha-fetoprotein; PT-activity, Prothrombin Time Activity; PT-INR, Prothrombin Time International Normalized Ratio; PTT, Partial Thromboplastin Time; WBC, White Blood Cells; RBC, Red Blood Cells; Hb, Haemoglobin; Ht, Haematocrit; Plt, Thrombocytes; CRP, C-Reactive Protein. Table 2Virology Prior to Systemic TreatmentAnti-HCVpositiveHCV-RNAN.D.HBs-AgN.D.Anti-HBs75 IU/lAbbreviations: Anti-HCV, Hepatitis C Virus Antibody; HCV-RNA, Hepatitis C Virus Ribonucleic Acid; HBs-Ag, Hepatitis B surface Antigen; Anti-HBs, Hepatitis B surface antibody; N.D., Not Detected. Virology Prior to Systemic Treatment Abbreviations: Anti-HCV, Hepatitis C Virus Antibody; HCV-RNA, Hepatitis C Virus Ribonucleic Acid; HBs-Ag, Hepatitis B surface Antigen; Anti-HBs, Hepatitis B surface antibody; N.D., Not Detected. The tumor board recommended primary systemic therapy with dual checkpoint inhibition due to extensive tumor burden with macrovascular infiltration. Because of the patient’s past medical history of gastrointestinal bleeding, a treatment with Bevacizumab (anti-VEGF antibody) was contraindicated and a regimen with Durvalumab and Tremelimumab according to the Single Tremelimumab Regular Interval Durvalumab (STRIDE) protocol was initiated.6 After four cycles of Durvalumab following a single priming dose of Tremelimumab, a restaging was performed. The imaging revealed a partial response after immunotherapy with a shrinkage of the lesion by 55% (85 mm x 45 mm x 45 mm) (Figure 2).11 Of note, treatment was well tolerated without any adverse events, liver function remained stable and distant metastases were absent. Thus, the tumor board opted for secondary resection. Figure 2CT imaging after systemic treatment. (a) Coronal view of the abdomen with the HCC (star) located in the liver showing partial response during the portal venous phase. (b) Axial view of the abdomen during the arterial phase with the HCC (star) in contact with the left portal vein (arrow).Two CT images depicting the lesion in the liver after systemic treatment. In both images the lesion has reduced in size. CT imaging after systemic treatment. (a) Coronal view of the abdomen with the HCC (star) located in the liver showing partial response during the portal venous phase. (b) Axial view of the abdomen during the arterial phase with the HCC (star) in contact with the left portal vein (arrow). Due to macrovascular invasion of the right anterior and left portal vein, a resection of segments I–V and VIII was necessary (left trisectionectomy). However, volumetric assessment of the future liver remnant after left trisectionectomy yielded a predicted future liver remnant (FLR) of 36% of total liver volume (Figure 3a). Therefore, a preoperative hypertrophy induction was indicated. A transhepatic portal vein embolization (PVE) was not considered to be technically feasible from the left or anterior portal branches. Because of a high risk for non-target embolization and trauma to the FLR, a contralateral transhepatic access by the posterior branches were not considered.12 Therefore, a two-step liver resection associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) was planned in a minimally invasive robotic approach. The right anterior and left portal veins were ligated, and the liver was transected between the right anterior and posterior section (Figure 3b). Surgery was performed using the DaVinci Xi robotic platform (Intuitive Surgical, Sunnyvale, CA, USA). Follow-up volumetric assessment on postoperative day 10 demonstrated a 10% increase of the future liver remnant resulting in 46% of total liver volume. Consequently, completion left trisectionectomy was performed (Figure 3b). Postoperative recovery was uneventful and the patient was discharged on the seventh postoperative day without any adverse events. Final pathology revealed a 60 x 40 x 55 mm tumor with negative resection margins (R0 resection) and no viable tumor cells. Notably, the specimen showed extensive necrosis—indicating a tumor regression grade 0 according to the Ryan classification (pathologic complete response, pCR) and ypT0 classification (Figure 3c). Figure 3Surgical resection of the HCC after neoadjuvant immunotherapy. (a) Pre-operative 3-dimensional volumetric assessment of the liver. (b) Intraoperative image during robotic ligation of the right anterior portal vein (arrow) supplying blood to segments V and VIII (star). (c) Specimen after resection with the large mass in the center (star).Three images demonstrating preoperative liver assessment, intraoperative view of the liver and the resected liver specimen. Surgical resection of the HCC after neoadjuvant immunotherapy. (a) Pre-operative 3-dimensional volumetric assessment of the liver. (b) Intraoperative image during robotic ligation of the right anterior portal vein (arrow) supplying blood to segments V and VIII (star). (c) Specimen after resection with the large mass in the center (star). At 12-month follow-up, the patient had an improved performance status (ECOG 0) without signs of recurrent disease or distant metastases, and liver function remained preserved (Figure 4, Table 3).Table 3Blood Laboratory Values at 6-Month Follow-UpNa+139 mmol/lAlb41 g/lK+4.9 mmol/lAFP3 µg/lCa2+2.5 mmol/lPT-activity68%Krea62 µmol/lPT-INR1.2eGFR94 mL/minPTT30.5 sec.T-Bil15 µmol/lWBC4.9 Giga/lAST74 U/lRBC5.2 Tera/lALT70 U/lHb14.5 g/dlGGT806 U/lHt0.44 L/lAKP376 U/lPlt186 Giga/lLDH140 U/lCRP3.8 mg/lAbbreviations: Na+, Sodium; K+, Potassium; Ca2+, Calcium; Krea, Creatinine; eGFR, estimated Glomerular Filtration Rate; T-Bil, Total Bilirubin; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; GGT, Gamma-Glutamyl Transferase; AKP, Alkaline Phosphatase; LDH, Lactate Dehydrogenase; Alb, Albumin; AFP, Alpha-fetoprotein; PT-activity, Prothrombin Time Activity; PT-INR, Prothrombin Time International Normalized Ratio; PTT, Partial Thromboplastin Time; WBC, White Blood Cells; RBC, Red Blood Cells; Hb, Haemoglobin; Ht, Haematocrit; Plt, Thrombocytes; CRP, C-Reactive Protein. Figure 4Imaging at 12-month follow-up. (a) Coronal view of the abdomen with the remaining liver segments VI, VII and I (star). (b) Axial view of the abdomen and remaining liver (star) 12 months after resection.Two CT images depicting the healthy remaining liver 12 months after surgery. Table 3Blood Laboratory Values at 6-Month Follow-UpNa+139 mmol/lAlb41 g/lK+4.9 mmol/lAFP3 µg/lCa2+2.5 mmol/lPT-activity68%Krea62 µmol/lPT-INR1.2eGFR94 mL/minPTT30.5 sec.T-Bil15 µmol/lWBC4.9 Giga/lAST74 U/lRBC5.2 Tera/lALT70 U/lHb14.5 g/dlGGT806 U/lHt0.44 L/lAKP376 U/lPlt186 Giga/lLDH140 U/lCRP3.8 mg/lAbbreviations: Na+, Sodium; K+, Potassium; Ca2+, Calcium; Krea, Creatinine; eGFR, estimated Glomerular Filtration Rate; T-Bil, Total Bilirubin; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; GGT, Gamma-Glutamyl Transferase; AKP, Alkaline Phosphatase; LDH, Lactate Dehydrogenase; Alb, Albumin; AFP, Alpha-fetoprotein; PT-activity, Prothrombin Time Activity; PT-INR, Prothrombin Time International Normalized Ratio; PTT, Partial Thromboplastin Time; WBC, White Blood Cells; RBC, Red Blood Cells; Hb, Haemoglobin; Ht, Haematocrit; Plt, Thrombocytes; CRP, C-Reactive Protein. Blood Laboratory Values at 6-Month Follow-Up Abbreviations: Na+, Sodium; K+, Potassium; Ca2+, Calcium; Krea, Creatinine; eGFR, estimated Glomerular Filtration Rate; T-Bil, Total Bilirubin; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; GGT, Gamma-Glutamyl Transferase; AKP, Alkaline Phosphatase; LDH, Lactate Dehydrogenase; Alb, Albumin; AFP, Alpha-fetoprotein; PT-activity, Prothrombin Time Activity; PT-INR, Prothrombin Time International Normalized Ratio; PTT, Partial Thromboplastin Time; WBC, White Blood Cells; RBC, Red Blood Cells; Hb, Haemoglobin; Ht, Haematocrit; Plt, Thrombocytes; CRP, C-Reactive Protein. Imaging at 12-month follow-up. (a) Coronal view of the abdomen with the remaining liver segments VI, VII and I (star). (b) Axial view of the abdomen and remaining liver (star) 12 months after resection. Discussion Advanced-stage hepatocellular carcinoma represents a highly heterogeneous patient cohort characterized by substantial variability in tumor burden, vascular invasion, liver function, and performance status.5,13 Although the BCLC staging system remains pivotal to therapeutic decision-making, its stage-based treatment recommendations may not adequately capture this heterogeneity. While the recent incorporation of the CUSE framework into the BCLC algorithm acknowledges the complexity of clinical decision-making, practical guidance for identifying candidates for treatment intensification or conversion remains limited.3,14 In this context, resectability in HCC should be reconsidered as a multidimensional concept encompassing both technical and biological components. Technical resectability is defined by the feasibility of achieving complete tumor removal with an adequate future liver remnant, whereas biological resectability reflects tumor aggressiveness and responsiveness to therapy.15 The latter remains difficult to assess due to the absence of validated biomarkers.16,17 However, clinical parameters such as macrovascular invasion and treatment response may serve as surrogate indicators of tumor biology.18,19 In patients with vascular invasion, upfront systemic therapy may therefore serve as a tool for biological selection, identifying patients who may benefit from subsequent surgical intervention.20 The present case exemplifies this evolving paradigm. Despite initial unresectability due to portal vein infiltration, dual immune checkpoint inhibition with Durvalumab and Tremelimumab resulted in significant tumor regression, enabling secondary resection with curative intent. The achievement of a complete pathologic response underscores the potential of immunotherapy-based conversion strategies in selected patients with advanced HCC. Current data on pathologic response rates and secondary resectability after neoadjuvant immunotherapy in advanced HCC remain limited to case reports and retrospective observational studies.19,21–23 Although adequate prospective data is missing in this setting, emerging evidence suggests that meaningful responses to immune checkpoint inhibitors may translate into improved surgical candidacy.19,24 A cross-trial analysis of neoadjuvant immune checkpoint inhibition demonstrated that a substantial proportion of patients achieve major or complete pathologic responses, even in the absence of marked radiologic tumor shrinkage.20–23 These trials, however, varied in cohort size ranging from 35 to 155 patients and type of treatment received (ICI in combination with TKIs or locoregional therapy).25 In addition, retrospective series combining immunotherapy with targeted or locoregional therapies have reported encouraging rates of secondary resection up to 36.8%.23,25,26 The pCR rate following neoadjuvant immunotherapy in HCC ranges from approximately 18–38%, depending on the regimen, patient population and definition used.11,19 However, data specifically stratified for BCLC stage C remains limited, as most neoadjuvant trials enrolled mixed populations. In this case, dual checkpoint inhibition was administered with Durvalumab and Tremelimumab. Durvalumab blocks PD-L1, thereby restoring PD-1/CD80-mediated T-cell activation, while Tremelimumab inhibits the cytotoxic T-lymphocate associated protein 4 (CTLA-4) to enhance early T-cell priming and expansion. Together, these mechanisms can produce a more potent and durable antitumor immune response.27 This complementary dual checkpoint blockade may have contributed to the profound tumor regression and complete pathological response observed in our patient, particularly by amplifying cytotoxic immune activity against residual viable tumor cells. These findings collectively support the concept of immunotherapy-driven downstaging as a clinically meaningful strategy in advanced HCC. Currently, multiple immunotherapy regimens are available for advanced-stage HCC.3 Aside from our case, there has only been one other reported case of pCR in the liver following STRIDE in BCLC-C HCC.28 Prospective data is warranted to support these retrospective findings as results from the NEOTOMA trial (NCT05440864), the first dedicated prospective evaluation of the STRIDE regimen in the neoadjuvant-to-resection pathway, are yet to be published.29 In addition, recent studies have highlighted emerging molecular and microenvironmental drivers of HCC progression and treatment resistance, underscoring the need for more individualized therapeutic strategies.30,31 In the present case, only a partial radiologic response was observed on imaging despite complete pathologic remission. Therefore, conventional assessment by Response Evaluation Criteria in Solid Tumors (RECIST) may underestimate treatment efficacy, as it does not fully capture immune-mediated tumor necrosis.19,32,33 This discordance highlights a key limitation of current response assessment by imaging and supports the role of surgical resection in eligible patients, both for definitive local control and evaluation of treatment response. However, although the observed pathological complete response is highly encouraging, spontaneous tumor necrosis cannot be entirely excluded, and pCR does not necessarily imply eradication of occult micrometastatic disease. Moreover, because this tumor was non-AFP-secreting at baseline and during follow-up, the case also highlights the limited value of alpha-1-fetoprotein (AFP) for response monitoring in this setting. This underscores the urgent need for reliable circulating biomarkers to reliably assess treatment response and detect recurrence in patients with non-AFP-secreting HCC. The etiology of HCC may constitute another key aspect for treatment allocation of patients. Notably, patients with hepatitis-related HCC demonstrated superior response to immunotherapy compared to non-viral etiology.34 The subset of viral HCC patients without cirrhosis has not been systematically evaluated as a distinct cohort for conversion therapy.35 Still, one has to consider that extended liver resections, particularly in cirrhotic patients, carry a significant risk of posthepatectomy liver failure.36 In the present case, the FLR of 36% was deemed insufficient for primary resection. Recent data shows that patients, particularly with history of liver disease such as viral hepatitis, may benefit from higher FLR thresholds at 40–45%.37 Preoperative hypertrophy induction decreases the risk of posthepatectomy liver failure. The current standard approach to induce liver hypertrophy remains PVE with or without hepatic vein embolization, while alternative techniques such as the ALPPS procedure carry higher morbidity rates.38 In the present case, a PVE was not deemed to be feasible, and therefore an ALPPS procedure was considered as an alternative technique using a robotic approach. ALPPS has been demonstrated to induce higher and faster hypertrophy rates compared to PVE, while morbidity rates remain high in unselected patient cohorts.39,40 Recent developments and modifications of the ALPPS technique including partial ALPPS and minimally invasive approaches have significantly reduced morbidity rates.41 At the same time, minimizing surgical trauma by minimally invasive techniques such as robotic surgery may preserve postoperative liver function.42 In the present case, a staged robotic major hepatectomy (left trisectionectomy after ALPPS) was performed with an uneventful postoperative course and improved performance status on follow-up. This illustrates that robot-assisted ALPPS can be feasible in an experienced center for carefully selected patients requiring rapid hypertrophy induction. Nonetheless, the present case report represents a hypothesis-generating observation and may reflect individual tumor biology and treatment responsiveness. Therefore, prospective controlled studies are warranted to define criteria for patient selection, timing of secondary surgery, and optimal treatment sequencing. Conclusion We demonstrated that neoadjuvant dual checkpoint inhibition with Durvalumab and Tremelimumab can achieve profound tumor regression and may enable secondary resectability in a case of an advanced HCC with macrovascular invasion. Given the heterogeneity of advanced HCC, individualized treatment strategies are essential. Incorporating systemic therapy as a tool for biological selection, combined with continuous reassessment for surgical candidacy, may enable selected patients to transition from palliative to curative-intent treatment. Further prospective studies are warranted to better define criteria for biological resectability and to optimize multidisciplinary management in this evolving field.